Drug Target Review

JULY 18, 2023

Artificial Intelligence (AI) is poised to transform the field of target discovery in drug development, offering immense potential to enhance efficacy, personalised medicine, and accelerate the development of innovative compounds. With support from pharmaceutical companies, ultimately, the answer to this question should be yes.

Drug Development 98

Drug Development Drugs Clinical Development Pharmaceutical Companies 98

DS in Pharmatics

FEBRUARY 27, 2023

When pharmaceutical companies develop a new drug product for the market, there are many different steps a potential product must go through to determine and control its safety, manufacturability, effectiveness and reliability. CMC is done during […]

Drug Development 52

Drug Development Pharmaceutical Companies Drugs Pharmaceuticals 52

Advarra

AUGUST 10, 2023

The Orphan Drug Act creates incentives for developing orphan drugs to treat such diseases. Operation Warp Speed for Rare Diseases looks to accelerate both drug development and approval. The post Operation Warp Speed for Rare Diseases: Expected Boom in Drug Development and Approval appeared first on Advarra.

Drug Development 52

Drug Development Disease Therapies Engineering 52

Alta Sciences

MARCH 27, 2024

Up Close and Personal With Eryn Corriveau, MSc, Senior Director, Drug Development and Regulatory Strategy nbartlett Wed, 03/27/2024 - 20:21 Here at Altasciences, Eryn is responsible for guiding regulatory strategies , conducting gap analyses, and leading interactions with regulatory agencies dur ing early drug development.

Drug Development 52

Drug Development Medical Schools Pharma Companies Drugs 52

Drug Patent Watch

AUGUST 26, 2024

The pharmaceutical industry has increasingly relied on Contract Development and Manufacturing Organizations (CDMOs) to support the development and commercialization of drugs. CDMOs offer a range of services, from drug development to manufacturing, allowing pharmaceutical companies to focus on their core competencies.

Pharmaceutical Companies 59

Pharmaceutical Companies Pharmaceuticals Drug Development Drugs 59

DrugBank

AUGUST 9, 2024

This high attrition rate directly results from the scientific and regulatory hurdles that drug candidates must overcome. The Investment Landscape Despite these challenges, the potential rewards for successful drug development are substantial. The market for cardiovascular drugs, valued at 155.6 reported in 2021.

Pharmaceuticals 77

Pharmaceuticals Research Pharmaceutical Companies Clinical Trials 77

PPD

MARCH 26, 2024

The PPD clinical research business of Thermo Fisher Scientific conducts an annual survey of more than 150 leaders at pharmaceutical companies around the globe to assess trends in drug discovery and development, including preferences around outsourcing and functional service provider (FSP) utilization.

Clinical Research 98

Clinical Research Pharmaceutical Companies Clinical Development Drug Development 98

DrugBank

NOVEMBER 4, 2024

While the demand for novel antibiotics is undeniable, the industry still struggles with the harsh realities of antibiotic drug development. This costly, high-risk development pipeline has high attrition rates and uncertain market returns.  

Pharmaceutical Companies 71

Pharmaceutical Companies Government Pharmaceuticals DNA 71

DrugBank

OCTOBER 4, 2024

Emerging Markets Emerging markets, particularly in Asia and Latin America, have become increasingly attractive destinations for pharmaceutical M&A activity. The growing middle class and government initiatives to improve access to medicines have created an ecosystem for pharmaceutical companies seeking growth opportunities.

Pharmaceuticals 81

Pharmaceuticals Pharmaceutical Companies Therapies Marketing 81

Drug Target Review

OCTOBER 14, 2024

Wilkie’s background as a biochemist and his time at Merck, a leading pharmaceutical company, shaped his early understanding of drug development and business strategy. As someone who describes himself as an “enthusiastic sceptic,” Wilkie is cautious but hopeful about the potential of AI in drug development. “I

Science 52

Science Pharmaceutical Companies Drug Development Pharmaceuticals 52

The Pharma Data

MAY 5, 2022

Validated Measurable Residual Disease Assays are Critical for the Rapid Development of Future Novel Therapeutics for Patients with Acute Myeloid Leukemia. Most often, AML develops from cells that would turn into white blood cells (other than lymphocytes), but sometimes AML develops in other types of blood-forming cells.

Disease 52

Disease Clinical Trials Drug Development Pharmaceutical Companies 52

DS in Pharmatics

FEBRUARY 24, 2023

Drug development is an immensely complex undertaking consisting of many different, interconnected processes. Specialist regulatory affairs consultants offer services to companies operating across this challenging industry.

Pharmaceutical Companies 52

Pharmaceutical Companies Regulations Drug Development Pharmaceuticals 52

H1 Blog

DECEMBER 4, 2023

As the pharmaceutical and biotech industries continue to push for faster drug development, the importance of equity and diversity in clinical trial recruitment cannot be overlooked. Let’s dive in to uncover the role of digital health and data in driving faster drug development through improved diversity.

Clinical Trials 59

Clinical Trials Trials Pharmaceutical Companies Drug Development 59

Conversations in Drug Development Trends

APRIL 4, 2024

The ICH M10 guidelines aim to streamline this process, reducing redundancy in drug development and facilitating faster access to new therapies. Understanding and implementing the ICH M10 guidelines is not just a regulatory requirement; it’s a step towards more efficient and effective pharmaceutical research.

Small Molecule 80

Small Molecule Clinical Trials Pharmaceuticals Pharmaceutical Companies 80

DrugBank

MARCH 7, 2024

The Quest for Ozempic-Like Alternatives Ozempic, a GLP-1 receptor agonist developed by Novo Nordisk, has demonstrated remarkable efficacy in promoting weight loss and improving metabolic health. Key Players and Challenges For pharmaceutical giants like Novo Nordisk and Eli Lilly, 2024 presents both opportunities and challenges.

Pharmaceutical Companies 81

Pharmaceutical Companies Clinical Trials Pharmaceuticals Therapies 81

Drug Target Review

SEPTEMBER 5, 2024

However, my goal was all the time to work with drug development in the pharma industry, so I moved on and started that journey in 1992 when I took on a role as Clinical Research Manager at AstraHässle, a mid-size Swedish pharma company.

Pharma Companies 111

Pharma Companies Licensing Licensing Disease 111

thought leadership

JUNE 19, 2023

Across biotech startups and global pharmaceutical companies alike, Veeva Vault continues to expand market share. With 1,300+ customers, Veeva Systems is one of the largest providers of cloud solutions for the life sciences industry.

Pharmaceutical Companies 40

Pharmaceutical Companies Drug Development Science Pharmaceuticals 40

H1 Blog

JULY 30, 2024

This sets the stage for binding and enforceable components per Section 3601 of the Food and Drug Omnibus Reform Act (FDORA), which will come into effect 180 days after the final guidance is published. Hence, pharmaceutical companies need to start making preparations to ensure compliance with the new requirements.

FDA 59

FDA Clinical Trials Compliance Pharma Companies 59

H1 Blog

MAY 4, 2023

Insights for Thought Leading Stakeholder Engagement to Decrease Medication Non-Adherence Pharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education.

Pharmaceutical Companies 52

Pharmaceutical Companies Clinical Research Pharma Companies Pharmaceuticals 52

Conversations in Drug Development Trends

DECEMBER 7, 2023

At Worldwide, we understand that every program is different, which means every drug development path forward will be unique. Rather than settling for an “off-the-shelf” approach, you deserve a team that actively seeks customized solutions tailored to your specific study.

Clinical Trials 136

Clinical Trials Clinical Development Trials Pharmaceutical Companies 136

PPD

JULY 20, 2023

Key competencies for biotech and biopharma organizations to meet the new USP requirements for plastic packaging and manufacturing materials With the implementation date drawing nearer, drug developers should test their packaging systems to ensure they are compliant and adhere to patient safety goals, or quickly identify and qualify alternatives.

Packaging 52

Packaging Laboratories Pharmaceutical Companies Compliance 52

PPD

JUNE 20, 2024

To accelerate clinical research timelines, pharmaceutical developers need to tap into solutions that demonstrably streamline drug development from start to finish. The finish line: Powering your success It’s time for pharmaceutical developers to make clinical research timelines work for them, not against them.

Clinical Research 52

Clinical Research Research Clinical Trials Pharmaceuticals 52

DrugBank

APRIL 12, 2024

Over the past decade, the drug discovery landscape has been revolutionized by the adoption of artificial intelligence (AI) and machine learning (ML), witnessing early adopters leapfrog into pioneering technologies aimed at streamlining the drug development process and curtailing associated costs.

Drugs 83

Drugs Clinical Trials Pharmaceutical Companies Pharmaceuticals 83

Altus Drug Development

JUNE 30, 2022

While this strategy is widely adopted by modern pharmaceutical companies, in recent years, its effectiveness has begun to wane. This novel approach promises to create great advantages for the pharmaceutical companies who adopt it and might become the future of medicine.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Treatment Production 52

H1 Blog

SEPTEMBER 14, 2023

As pharmaceutical companies turn to CROs (Clinical Research Organizations) for trial design and technology, there are new opportunities emerging with healthcare data intelligence that can help ensure a bright future for the industry and to make trials more effective, efficient and accessible. million data points.”

Clinical Trials 59

Clinical Trials Pharmaceutical Companies Trials Pharmaceuticals 59

FDA Law Blog: Drug Discovery

MARCH 6, 2024

Charles assists clients across a range of FDA-related regulatory matters by providing timely strategic advice on new drug and biologic development and helping them tackle complex regulatory issues.

FDA 59

FDA Compliance Pharmaceuticals Pharmaceutical Companies 59

Drug Target Review

AUGUST 15, 2023

Prochownik, delved into the dual role of the Myc gene in both cancer development and ageing. The findings highlight the gene’s complex functions, opening up new avenues for cancer therapy and raising important considerations for future drug development.

Research 98

Research Pharmaceutical Companies Drug Development Therapies 98

Drug Target Review

SEPTEMBER 19, 2023

In addition, these models at the current state are better for short term tests, over a week or two and cannot be used for acquiring data from long term drug exposures. Miniature organs as test beds for new drugs Organoids are miniature human organs with clusters of cells derived from stem cells and mimic specific tissues.

Animal Testing 98

Animal Testing Clinical Trials Pharmaceutical Companies FDA 98

Advarra

APRIL 4, 2024

Continuity of Experience Imagine a pharmaceutical company is embarking on a series of clinical trials for a particular therapeutic area, such as oncology or neurology. This continuity of experience enables the DSMB to provide the pharmaceutical company with more nuanced and informed recommendations throughout the entire program.

Clinical Trials 52

Clinical Trials Pharmaceutical Companies Trials FDA 52

Conversations in Drug Development Trends

APRIL 15, 2024

As the clinical research landscape continually evolves, the choice of a Contract Research Organization (CRO) partner can significantly impact the success of drug development programs.

Clinical Trials 52

Clinical Trials Clinical Development Clinical Research Pharmaceutical Companies 52

Crown Bioscience

MAY 4, 2021

Among the 180+ cancer drugs approved by the FDA since 1995, only 14 have been approved for pediatric use, with another 26 used off-label (i.e. used in a way that is not described in the license), and only three drugs have been approved exclusively for use in children.

Research 52

Research Pharmaceutical Companies Licensing Licensing 52

H1 Blog

JUNE 8, 2023

In this blog post, we’ll explore how early diversity in HCP engagement can drive better outcomes and equity in drug development. The drug development process is known to be often expensive, lengthy, and full of trial and error before finding success.

Drug Development 52

Drug Development Science Pharmaceutical Companies Production 52

Drug Target Review

JANUARY 5, 2024

Scientists from the Centre for Genomic Regulation and the Wellcome Sanger Institute have found the allosteric control sites in the KRAS protein, the highly sought after targets for drug development. In drug development, allosteric sites are preferred because they provide better specificity, reducing the likelihood of side effects.

Regulations 98

Regulations Pharmaceutical Companies DNA Drug Development 98

Molecule Blog

JULY 11, 2023

“Show me the incentive and I’ll show you the outcome”  — Charlie Munger Introduction Five years ago, we started building Molecule around a simple yet powerful idea: to place patients and researchers at the center of the drug development process. In the context of this model, what is a good drug? This is a very powerful concept.

Government 40

Government Drug Development Pharmaceutical Companies Research 40

Drug Target Review

JANUARY 8, 2024

We are at the forefront of drug development in an area of research called cellular rejuvenation, which is an approach that has the potential to address many diseases of ageing by restoring aged and injured cells to a more youthful and resilient state. a commercial stage pharmaceutical company.

Science 145

Science Disease FDA Approval Clinical Trials 145

Drug Target Review

FEBRUARY 1, 2024

But commitment to neuroscience drug development is critically important given the significant unmet medical needs and the ways in which patients, caregivers, and families suffer. As soon as drug developers can begin to develop conviction, momentum increases. It’s a great example of how our model works.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

Predictive Oncology

FEBRUARY 7, 2023

What happens if we are able to provide information to the pharmaceutical company that doubles that [and] one in 10 molecules actually make it?” The next step was to validate the predictions and learn whether the drugs really produce a response in the specific tumor type.

Clinical Trials 52

Clinical Trials Pharmaceutical Companies Trials Pharmaceuticals 52